Medesis Pharma Extends Collaboration in Biopharm Sector
Medesis Pharma has signed a collaboration agreement with the French Commission for Atomic Energy and Alternative Energies
Medesis Pharma, a biopharmaceutical company represented in France and Canada, has signed a collaboration agreement with the French Commission for Atomic Energy and Alternative Energies (Commissariat à l'énergie atomique et aux énergies alternatives, CEA) on the development of compounds designed to remove radioactive/toxic metal contaminants from the body.
Medesis Pharma is targeting the defense markets and the civil nuclear industry (especially governmental stocks of decorporation products for civil protection in the vicinity of nuclear power plants). At present, there are no appropriate marketed products to use on a broad population for decorporation of plutonium and cesium, and there is no treatment for the decorporation of uranium, according to the company.
"Here at Medesis Pharma, we are delighted to extend and formalize our collaboration with CEA - simply the best possible partner for many opportunities in this part of the pharmaceutical market," commented Pharma Medesis' CEO Jean-Claude Maurel.
Meanwhile, Eric Quémeneur (Program and Research Exploitation Director in the CEA's Life Sciences Department) welcomed the opportunity to jointly develop original compounds in under-explored therapeutic areas.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
